Zai Lab (ZLAB) Drug Pipeline

The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness

A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.

Zai Lab ZLAB is currently developing the following drugs: Atezolizumab, Zl-1310, Obrixtamig, Zl-6201, Zl-1310, Investigator's Choice Of Therapy, Tacrolimus, Povetacicept, Zl-1310, Carboplatin, Atezolizumab, Zl-1310. These drug candidates are in various stages of clinical development as the company works toward FDA approval.